Have a feature idea you'd love to see implemented?
Let us know!
PDSB PDS Biotechnology Corp
Price (delayed)
$2.17
Market cap
$81.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.17
Enterprise value
$56.1M
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively
Highlights
PDS Biotechnology's EPS has increased by 32% YoY and by 4.9% QoQ
PDS Biotechnology's net income has increased by 21% YoY
The quick ratio has plunged by 54% YoY and by 26% from the previous quarter
The equity has contracted by 29% from the previous quarter and by 10% YoY
Key stats
What are the main financial stats of PDSB
Market
Valuations
Earnings
Shares outstanding
37.41M
Market cap
$81.18M
Enterprise value
$56.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.63
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$39.37M
EBITDA
-$39.35M
Free cash flow
-$35.25M
Per share
Balance sheet
Liquidity
EPS
-$1.17
Free cash flow per share
-$0.96
Book value per share
$0.6
Revenue per share
$0
TBVPS
$1.43
Total assets
$52.45M
Total liabilities
$30.45M
Debt
$24.67M
Equity
$22M
Working capital
$33.79M
Debt to equity
1.12
Current ratio
2.84
Quick ratio
2.71
Net debt/EBITDA
0.64
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-67.2%
Return on equity
-139.6%
Return on invested capital
-350.2%
Return on capital employed
-115.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PDSB stock price
How has the PDS Biotechnology stock price performed over time
Intraday
8.5%
1 week
-0.91%
1 month
-32.82%
1 year
-57.95%
YTD
-56.34%
QTD
-43.19%
Financial performance
How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.37M
Net income
-$40.56M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 23% YoY
PDS Biotechnology's net income has increased by 21% YoY
Growth
What is PDS Biotechnology's growth rate over time
Valuation
What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
3.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 32% YoY and by 4.9% QoQ
The P/B is 32% lower than the last 4 quarters average of 4.9 and 12% lower than the 5-year quarterly average of 3.8
The equity has contracted by 29% from the previous quarter and by 10% YoY
Efficiency
How efficient is PDS Biotechnology business performance
PDS Biotechnology's ROIC has decreased by 29% YoY and by 18% from the previous quarter
The ROA is up by 13% YoY
PDSB's ROE is up by 3.2% YoY
Dividends
What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PDSB.
Financial health
How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 72% more than its total liabilities
The quick ratio has plunged by 54% YoY and by 26% from the previous quarter
PDSB's current ratio has dropped by 54% year-on-year and by 26% since the previous quarter
PDS Biotechnology's debt is 12% higher than its equity
The debt to equity is up by 42% since the previous quarter and by 17% year-on-year
The equity has contracted by 29% from the previous quarter and by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.